knowledge -WSS

knowledge

author：fashion 2025-09-30 00:49:30 - browse：5163

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： How many hemophilia patients actually want gene therapy?

WSS

Senate panel clears PBM, hopsital reforms

HPV cancer vaccine study demonstrates efficacy

STAT Executive Editor Rick Berke on STAT's 8th birthday

UCLA team creates talking throat patch for voice disorders

Medicare solvency divides Republicans at the presidential debate

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

knowledge

explore

In age of alternative facts, a scholarly course on calling out crap

The new shift in health care is toward less care

23andMe had bad news about my health. I wish a person had delivered it

Study: New antibiotic targets gonorrhea as well as last existing drug

After affirmative action ruling, medical educators look to 'holistic review'

Extreme heat events are a public health emergency

Cancer drug shortages should be causing more outrage

A clever new way to fix Medicaid and graduate medical education

How one medical school became remarkably diverse

HPV cancer vaccine study demonstrates efficacy

Wikipedia

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

John Green on his newest strategy for fighting tuberculosis

EPA limits use of carcinogenic gas for sterilizing medical devices

Will General Catalyst be the first of many hospital takeovers?

First U.S. drug developed to treat liver disease MASH is approved

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

focus

hotspot

entertainment

focus